Courbevoie, France

Marie-Claire Rettori


Average Co-Inventor Count = 7.6

ph-index = 5

Forward Citations = 68(Granted Patents)


Location History:

  • Courbervoie, FR (1997)
  • Courbevoie, FR (1996 - 1999)

Company Filing History:


Years Active: 1996-1999

Loading Chart...
10 patents (USPTO):Explore Patents

Title: The Innovative Journey of Inventor Marie-Claire Rettori

Introduction:

Marie-Claire Rettori, a prolific inventor based in Courbevoie, France, has made significant strides in the field of pharmaceuticals with an impressive portfolio of 10 patents. He is known for his groundbreaking work in developing compounds with applications as Imidazoline receptor ligands and D.sub.4 receptor ligands.

Latest Patents:

Rettori's latest patents include Imidazoline compounds, characterized by their formula (I) with diverse R variations, alongside their isomers and pharmaceutically acceptable acid addition salts. Moreover, his contributions extend to Heterocyclic aminomethyl compounds, featuring a general formula (I) beneficial as D.sub.4 receptor ligands. These medicinal products exhibit promising potential in therapeutic applications.

Career Highlights:

Having excelled in his profession, Marie-Claire Rettori is affiliated with Adir et Compagnie, an esteemed company at the forefront of innovation in the pharmaceutical sector. His tenure at Adir et Compagnie has been marked by groundbreaking research and inventive solutions that have garnered recognition within the industry.

Collaborations:

Throughout his career, Rettori has collaborated closely with accomplished peers like Pierre Renard and Daniel-Henri Caignard. Together, they have forged strong professional relationships, pooling their expertise to explore new frontiers in pharmaceutical research and development.

Conclusion:

Marie-Claire Rettori's journey as an inventor showcases a relentless pursuit of innovation and a commitment to advancing pharmaceutical sciences. His valuable contributions in patenting novel compounds underscore his position as a trailblazer in the field, leaving an indelible mark on the realm of pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…